Alchemab Therapeutics
PrivateLast Round
Series A
Extension
Jul 9, 2026
Total Funding Raised
$116M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Alchemab Therapeutics is a biotechnology company that develops novel therapeutic antibodies by analyzing patient antibody repertoires from disease-resilient individuals.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alchemab Therapeutics Comparables
Compare Alchemab Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OncoResponse | 78% | |
| Macomics | 75% | |
| Mestag Therapeutics | 71% | |
Alchemab Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jul 9, 2026 | ||||
| Series A Extension | Sep 9, 2025 | ||||
| Grant | Dec 16, 2022 | ||||
| Series A | Apr 15, 2021 | ||||
| Accelerator | May 12, 2020 |
Key People
Founding team and executive leadership
Alchemab Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A Extension, Series A |
| SV Health Investors | Series A, Series A Extension, Seed |
| DCVC Bio | Seed, Series A Extension |
| Camford Capital | Series A |
| Lightstone Ventures | Series A, Series A Extension |
| British Business Bank | Series A Extension |
| Innovate UK | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 9, 2026
$34M round led by British Business Bank.
- Mar 17, 2026
Dr. Ulrich Wendt appointed as Chief Business Officer.
Alchemab Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Alchemab Therapeutics's valuation, stock price, and market status.